Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms

Olga Dashevsky, PhD, Ricardo De Matos Simoes, PhD, Ryosuke Shirasaki, MD, Michal Sheffer, PhD, Eugen Dhimolea, PhD, Sara Gandolfi, MD, Huihui Tang, PhD, Sondra L. Downey-Kopyscinski, PhD, Megan Bariteau, B.Sc., Jeffrey Sorrell, BA, Brian Glassner, PhD, John Doench, PhD, Larry H. Boise, PhD, Jonathan D. Licht, MD, Aedin Culhane, PhD, William C. Hahn, MD PhD, Francisca Vazquez, PhD, Aviad Tsherniak, PhD, Constantine S. Mitsiades, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-142651

Published: 2020

Journal Articles

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Blood (2019) 134 (Supplement_1): 318.

https://doi.org/10.1182/blood-2019-130549

Published: 2019

Journal Articles

Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma

Blood (2019) 134 (Supplement_1): 4407.

https://doi.org/10.1182/blood-2019-130901

Published: 2019

Journal Articles

Functional Genomic Landscape of Genes with Recurrent Mutations in Multiple Myeloma

Ricardo De Matos Simoes, PhD, Ryosuke Shirasaki, MD PhD, Huihui Tang, PhD, Michal Sheffer, PhD, Olga Dashevsky, PhD, Sara Gandolfi, MD, Eugen Dhimolea, PhD, Megan Bariteau, BSc, Jonathan D. Licht, MD, Brian Glassner, PhD, Richard WJ Groen, PhD, Joan Levy, PhD, Daniel Auclair, PhD, Francisca Vazquez, PhD, Aviad Tsherniak, PhD, William C. Hahn, MD PhD, Aedin Culhane, PhD, Constantine S. Mitsiades, MD PhD

Blood (2018) 132 (Supplement 1): 189.

https://doi.org/10.1182/blood-2018-189

Published: 2018

Journal Articles

CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

Blood (2018) 132 (Supplement 1): 1367.

https://doi.org/10.1182/blood-2018-99-116232

Published: 2018

Journal Articles

Integration of Functional Dependencies and Molecular Alterations of Myeloma Cells

Blood (2017) 130 (Supplement 1): 1212.

https://doi.org/10.1182/blood.V130.Suppl_1.1212.1212

Published: 2017

Journal Articles

Functional Genomic Landscape of Epigenetic Dependencies in Myeloma

Ricardo De Matos Simoes, PhD, Geoffrey Matthews, PhD, Daphne Dupere Richer, PhD, Ryosuke Shirasaki, MD, Michal Sheffer, PhD, Olga Dashevsky, PhD, Sara Gandolfi, MD, Eugen Dhimolea, PhD, Brian Glassner, PhD, Richard WJ Groen, PhD, Franciska Vazquez, PhD, Joshua Dempster, PhD, Aviad Tsherniak, PhD, William C. Hahn, MD PhD, Aedin Culhane, PhD, Jonathan D. Licht, MD, Constantine S. Mitsiades, MD PhD

Blood (2017) 130 (Supplement 1): 1209.

https://doi.org/10.1182/blood.V130.Suppl_1.1209.1209

Published: 2017

Journal Articles

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

Xiangao Huang, PhD, David Jayabalan, BSMS, MSc, Maurizio Di Liberto, PhD, Zhengming Chen, PhD, Anna C Schinzel, PhD, Scott Ely, MD MPH, Adriana C Rossi, MD MHS, Roger N Pearse, MD PhD, Ekta Aneja, MBBS, Morton Coleman, MD, Joseph M Lane, MD, William C. Hahn, MD PhD, Tomer M Mark, MD MSc, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2015) 126 (23): 500.

https://doi.org/10.1182/blood.V126.23.500.500

Published: 2015

Journal Articles

Sensitizing shRNA Screen for Molecular Targets in CDK4/CDK6-Based Combination Therapy in Multiple Myeloma

Xiangao Huang, PhD, Maurizio Di Liberto, PhD, David Chiron, PhD, Ruben Niesvizky, MD, Anna C. Schinzel, PhD, William C. Hahn, MD PhD, Selina Chen-Kiang, PhD

Blood (2014) 124 (21): 3440.

https://doi.org/10.1182/blood.V124.21.3440.3440

Published: 2014

Journal Articles

Requirement For CDK6 In MLL-Rearranged Acute Myeloid Leukemia

Theresa Placke, PhD, Katrin Faber, PhD, Atsushi Nonami, MD, Helmut R. Salih, MD, Stephen M. Sykes, PhD, David E. Root, PhD, David A. Barbie, MD, William C. Hahn, MD, PhD, Michael D. Milsom, PhD, Claudia Scholl, MD, Stefan Fröhling, MD

Blood (2013) 122 (21): 3782.

https://doi.org/10.1182/blood.V122.21.3782.3782

Published: 2013

Journal Articles

Genome-Wide RNAi Screen Identifies The Mechanistic Role For DOT1L In MLL -Rearranged Leukemia

Chun-Wei David Chen, Ph.D., Amit U. Sinha, PhD, Jun Qi, Ph.D., Aniruddha J Deshpande, Ph.D., Nan Zhu, PhD, Richard Koche, Ph.D., Rowena Eng, Jenny Chang, William C. Hahn, MD, PhD, James E Bradner, MD, Scott A. Armstrong, MD, PhD

Blood (2013) 122 (21): 598.

https://doi.org/10.1182/blood.V122.21.598.598

Published: 2013

Journal Articles

Synergistic Loss of IRF4 and Induction of IRF7 Sensitizes Primary Myeloma Cells to IMiD Killing by IFNβ in Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition

Xiangao Huang, PhD, David Jayabalan, B.S.M.S, Maurizio Di Liberto, Ph.D., Jackson D Harvey, B.S., Anna C. Schinzel, PhD, Tomer M Mark, MD, MSc, Mohamad Hussein, MD, Sophia Randolph, MD, PhD, William C. Hahn, MD, PhD, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2012) 120 (21): 572.

https://doi.org/10.1182/blood.V120.21.572.572

Published: 2012

Journal Articles

Inhibition of c-Myc Expression and Function in Hematologic Malignancies

Blood (2011) 118 (21): 1409.

https://doi.org/10.1182/blood.V118.21.1409.1409

Published: 2011

Journal Articles

Intersecting Chemical Genomic and Genetic Screens Identifies Glycogen Synthase Kinase-3α (GSK-3α) as a Modulator of Differentiation In Acute Myeloid Leukemia

Versha Banerji, MD, Kenneth N. Ross, PhD, Loretta S. Li, MD, Stacey M. Frumm, Anna C. Schinzel, PhD, Cynthia K. Hahn, Rose M. Kakoza, MD, Kwan T. Chow, Linda Ross, PhD, Haig Inguilizian, MD, Ilene Galinsky, ANP, Richard M Stone, MD, Daniel J DeAngelo, MD, PhD, William C. Hahn, MD, PhD, Andrew L. Kung, MD, PhD, Kimberly Stegmaier, MD

Blood (2010) 116 (21): 1000.

https://doi.org/10.1182/blood.V116.21.1000.1000

Published: 2010

Journal Articles

HOXA9 Is a Novel Therapeutic Target in Multiple Myeloma.

Michael A Chapman, Jean-Philippe Brunet, Jonathan J Keats, PhD, Angela Baker, Mazhar Adli, Anna C. Schinzel, Gregory Ahmann, BS, Harview Christina, Anna Moore, Vijayalakshmi Shanmugam, Louise M. Perkins, PhD, Daniel Auclair, PhD, William C. Hahn, MD, PhD, Bradley E. Bernstein, MD, Leif Bergsagel, Rafael Fonseca, John Carpten, Jeffrey Trent, Todd R. Golub, MD

Blood (2009) 114 (22): 832.

https://doi.org/10.1182/blood.V114.22.832.832

Published: 2009

Journal Articles

NOVEL Pathways Modulate TUMOR CELL Susceptibility to NK CELLS.

Roberto Bellucci, Ph.D, Hong-Nam Nguyen, Allison Martin, Anna C. Schinzel, PhD, Stefan Heinrichs, PhD, William C. Hahn, MD, PhD, Jerome Ritz, MD

Blood (2009) 114 (22): 277.

https://doi.org/10.1182/blood.V114.22.277.277

Published: 2009

Journal Articles

A High-Throughput Arrayed Lentiviral RNAi Screen To Identify Novel Oncogenes in Multiple Myeloma.

Anna C. Schinzel, PhD, Mike Chapman, MD, Ben Wittner, PhD, Yashaswi Shrestha, Sridhar Ramaswamy, MD, Todd R. Golub, MD, William C. Hahn, MD, PhD

Blood (2007) 110 (11): 4770.

https://doi.org/10.1182/blood.V110.11.4770.4770

Published: 2007

NARROW

Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma

Functional Genomic Landscape of Genes with Recurrent Mutations in Multiple Myeloma

CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

Integration of Functional Dependencies and Molecular Alterations of Myeloma Cells

Functional Genomic Landscape of Epigenetic Dependencies in Myeloma

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

Sensitizing shRNA Screen for Molecular Targets in CDK4/CDK6-Based Combination Therapy in Multiple Myeloma

Requirement For CDK6 In MLL-Rearranged Acute Myeloid Leukemia

Genome-Wide RNAi Screen Identifies The Mechanistic Role For DOT1L In MLL -Rearranged Leukemia

Synergistic Loss of IRF4 and Induction of IRF7 Sensitizes Primary Myeloma Cells to IMiD Killing by IFNβ in Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition

Inhibition of c-Myc Expression and Function in Hematologic Malignancies

Intersecting Chemical Genomic and Genetic Screens Identifies Glycogen Synthase Kinase-3α (GSK-3α) as a Modulator of Differentiation In Acute Myeloid Leukemia

HOXA9 Is a Novel Therapeutic Target in Multiple Myeloma.

NOVEL Pathways Modulate TUMOR CELL Susceptibility to NK CELLS.

A High-Throughput Arrayed Lentiviral RNAi Screen To Identify Novel Oncogenes in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only